NEW YORK (GenomeWeb) – Ag-bio firm Arcadia Biosciences announced today that has it acquired a worldwide, nonexclusive license to the Broad Institute's intellectual property on CRISPR-Cas9 genome-editing technology.

According to Arcadia, the research-use license allows it to use the patented technology to develop nutritional and agricultural productivity traits in its core crops. Additional terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.